A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

PHASE3RecruitingINTERVENTIONAL
Enrollment

520

Participants

Timeline

Start Date

December 27, 2024

Primary Completion Date

December 23, 2030

Study Completion Date

April 6, 2032

Conditions
Multiple MyelomaNewly Diagnosed Multiple Myeloma
Interventions
DRUG

Belantamab mafodotin

Belantamab mafodotin will be administered.

DRUG

Lenalidomide

Lenalidomide will be administered.

DRUG

Dexamethasone

Dexamethasone will be administered.

DRUG

Daratumumab

Daratumumab will be administered.

Trial Locations (81)

807

RECRUITING

GSK Investigational Site, Kaohsiung City

1200

RECRUITING

GSK Investigational Site, Brussels

1414

RECRUITING

GSK Investigational Site, Ciudad Autonoma de Buenos Aire

2250

RECRUITING

GSK Investigational Site, Gosford NSW

3128

RECRUITING

GSK Investigational Site, Box Hill

7301

RECRUITING

GSK Investigational Site, Hornu

8000

RECRUITING

GSK Investigational Site, Bruges

8800

RECRUITING

GSK Investigational Site, Roeselare

9000

RECRUITING

GSK Investigational Site, Ghent

10002

RECRUITING

GSK Investigational Site, Taipei

26504

RECRUITING

GSK Investigational Site, Pátrai

28007

RECRUITING

GSK Investigational Site, Madrid

28041

RECRUITING

GSK Investigational Site, Madrid

29010

RECRUITING

GSK Investigational Site, Málaga

30120

RECRUITING

GSK Investigational Site, Murcia

33394

RECRUITING

GSK Investigational Site, Gijón

36607

RECRUITING

GSK Investigational Site, Mobile

39011

RECRUITING

GSK Investigational Site, Santander

44033

RECRUITING

GSK Investigational Site, Ulsan

44202

RECRUITING

GSK Investigational Site, Nantes

47003

RECRUITING

GSK Investigational Site, Valladolid

47014

RECRUITING

GSK Investigational Site, Meldola FC

54007

RECRUITING

GSK Investigational Site, Thessaloniki

77339

RECRUITING

GSK Investigational Site, Kingwood

93009

RECRUITING

GSK Investigational Site, Bobigny

94805

RECRUITING

GSK Investigational Site, Villejuif

100191

RECRUITING

GSK Investigational Site, Beijing

200080

RECRUITING

GSK Investigational Site, Shanghia

210008

RECRUITING

GSK Investigational Site, Nanjing

300020

RECRUITING

GSK Investigational Site, Tianjin

325000

RECRUITING

GSK Investigational Site, Wenzhou

330000

RECRUITING

GSK Investigational Site, Nanchang

510515

RECRUITING

GSK Investigational Site, Guangzhou

518039

RECRUITING

GSK Investigational Site, Shenzhen

C1426ANZ

RECRUITING

GSK Investigational Site, Capital Federal

Unknown

RECRUITING

GSK Investigational Site, Córdoba

RECRUITING

GSK Investigational Site, Fitzroy

RECRUITING

GSK Investigational Site, Nanchang

RECRUITING

GSK Investigational Site, Athens

RECRUITING

GSK Investigational Site, Waterford

RECRUITING

GSK Investigational Site, Ancona

RECRUITING

GSK Investigational Site, Lublin

RECRUITING

GSK Investigational Site, Badalona

RECRUITING

GSK Investigational Site, Madrid

RECRUITING

GSK Investigational Site, Salamanca

S2002

RECRUITING

GSK Investigational Site, Rosario

R8500ACE

RECRUITING

GSK Investigational Site, Viedma

708 52

RECRUITING

GSK Investigational Site, Ostrava

01307

RECRUITING

GSK Investigational Site, Dresden

68 100

RECRUITING

GSK Investigational Site, Alexandroupoli

106 76

RECRUITING

GSK Investigational Site, Athens

115 28

RECRUITING

GSK Investigational Site, Athens

D09V2N0

RECRUITING

GSK Investigational Site, Dublin

00161

RECRUITING

GSK Investigational Site, Roma

467-8602

RECRUITING

GSK Investigational Site, Aichi

790-0024

RECRUITING

GSK Investigational Site, Ehime

790-8524

RECRUITING

GSK Investigational Site, Ehime

815-8555

RECRUITING

GSK Investigational Site, Fukuoka

960-1295

RECRUITING

GSK Investigational Site, Fukushima

371-8511

RECRUITING

GSK Investigational Site, Gunma

660-8550

RECRUITING

GSK Investigational Site, Hyōgo

670-8540

RECRUITING

GSK Investigational Site, Hyōgo

300-0028

RECRUITING

GSK Investigational Site, Ibaraki

920-8641

RECRUITING

GSK Investigational Site, Ishikawa

211-8510

RECRUITING

GSK Investigational Site, Kanagawa

983-8520

RECRUITING

GSK Investigational Site, Miyagi

632-8552

RECRUITING

GSK Investigational Site, Nara

028-3695

RECRUITING

GSK Investigational Site, Numakunai

003-0006

RECRUITING

GSK Investigational Site, Sapporo

565-0871

RECRUITING

GSK Investigational Site, Suita

105-8471

RECRUITING

GSK Investigational Site, Tokyo

990-9585

RECRUITING

GSK Investigational Site, Yamagata

519-763

RECRUITING

GSK Investigational Site, Hwasun

561-712

RECRUITING

GSK Investigational Site, Jeonju

03080

RECRUITING

GSK Investigational Site, Seoul

03722

RECRUITING

GSK Investigational Site, Seoul

06351

RECRUITING

GSK Investigational Site, Seoul

06591

RECRUITING

GSK Investigational Site, Seoul

138-736

RECRUITING

GSK Investigational Site, Seoul

08035

RECRUITING

GSK Investigational Site, Barcelona

PL6 8DH

RECRUITING

GSK Investigational Site, Plymouth

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT06679101 - A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) | Biotech Hunter | Biotech Hunter